Related Experiment Video

Updated: Mar 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Panobinostat for the management of multiple myeloma

Dharshan Sivaraj1, Michael M Green1, Cristina Gasparetto1

  • 1Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

Future Oncology (London, England)
|October 26, 2016
PubMed

Insights

Panobinostat, a novel deacetylase inhibitor, offers a new therapeutic option for multiple myeloma (MM). This review explores its biology, efficacy, and future potential in treating this incurable blood cancer.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a prevalent blood cancer with limited curative options.
  • Despite treatment advancements, MM remains largely incurable, necessitating novel therapeutic strategies.
  • Panobinostat represents a new class of drugs targeting cancer cell survival mechanisms.

Purpose of the Study:

  • To review the biological mechanisms of panobinostat.
  • To summarize the clinical efficacy of panobinostat in MM treatment.
  • To explore future applications of panobinostat in various MM settings.

Main Methods:

  • Literature review of preclinical and clinical studies on panobinostat.
  • Analysis of FDA approval data and ongoing clinical trials.
  • Synthesis of information on panobinostat's mechanism of action and therapeutic outcomes.

Main Results:

  • Panobinostat is a pan-deacetylase inhibitor approved for relapsed/refractory MM.
  • Clinical trials are investigating panobinostat in diverse MM treatment scenarios.
  • The drug functions by inhibiting deacetylase enzymes, impacting protein stability.

Conclusions:

  • Panobinostat is a valuable addition to the MM therapeutic arsenal.
  • Further research is warranted to optimize panobinostat's role in MM management.
  • Exploring panobinostat in different MM contexts may improve patient outcomes.
Keywords:
HDAC inhibitorPANORAMAimmunomodulationinduction therapymaintenance therapymultiple myelomapanobinostatplasma cell dyscrasiarelapsed/refractoryvorinostat

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
884
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K